Skip to main content

Prometheus Biosciences, Inc. (RXDX)

NASDAQ: RXDX · IEX Real-Time Price · USD
26.00 1.04 (4.17%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap1.01B
Revenue (ttm)1.91M
Net Income (ttm)n/a
Shares Out38.81M
EPS (ttm)-3.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume208,468
Open25.01
Previous Close24.96
Day's Range24.87 - 26.38
52-Week Range16.11 - 30.64
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 10, 2021

About RXDX

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb ...

IndustryBiotechnology
IPO DateMar 12, 2021
Employees24
Stock ExchangeNASDAQ
Ticker SymbolRXDX
Full Company Profile

Financial Performance

In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.

Financial Statements

News

Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Off...

1 week ago - GlobeNewsWire

Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) -

2 months ago - GlobeNewsWire

In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed awa...

2 months ago - GlobeNewsWire

Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Pla...

-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600-

4 months ago - GlobeNewsWire

Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...

4 months ago - GlobeNewsWire

3 Small Cap Stocks That Are Short Squeeze Candidates

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

Other symbols:GTHWRLD
5 months ago - Benzinga

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...

5 months ago - GlobeNewsWire

3 Short Squeeze Candidates In The Health Care Sector

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

Other symbols:THMOVYNT
5 months ago - Benzinga

Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today

Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.

Other symbols:CYDY
6 months ago - Benzinga

Steven Cohen Dives Deeper Into Health Care

Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-Ti...

Other symbols:AMDCRISFBGOOGLMSFTV
6 months ago - GuruFocus

The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

7 months ago - Benzinga

Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purc...

SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercializat...

7 months ago - PRNewsWire

Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development,...

7 months ago - PRNewswire

Phase 1 biotech Prometheus Biosciences files for a $125 million IPO

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public offering.

8 months ago - NASDAQ

Prometheus Biosciences IPO Registration Document (S-1)

Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC